{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:31:23Z","timestamp":1770298283634,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.transci.2022.103455","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T03:42:46Z","timestamp":1652240566000},"page":"103455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patients"],"prefix":"10.1016","volume":"61","author":[{"given":"Akanksha","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanvi","family":"Jha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Gogoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeti","family":"Diwaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Maroof","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok Kumar","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2022.103455_bib1","unstructured":"WHO Pandemia, 2020. WHO Director-General\u2019s opening remarks at the media briefing on COVID-19 - 11 March 2020, Who Health 6 BioMed Research International Organization Site, 2020, https:\/\/www.who.int\/dg\/speeches\/ detail\/who-director-general-s-opening-remarks-at-themedia-briefing-on-covid-19\u201411-march-2020."},{"issue":"1","key":"10.1016\/j.transci.2022.103455_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/07853890.2020.1861644","article-title":"The cardiovascular aspect of COVID-19","volume":"53","author":"Adu-Amankwaah","year":"2021","journal-title":"Ann Med"},{"issue":"1","key":"10.1016\/j.transci.2022.103455_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.691","article-title":"Therapeutic approaches against coronaviruses acute respiratory syndrome","volume":"9","author":"Servidio","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.transci.2022.103455_bib4","first-page":"2020.08","article-title":"Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience","volume":"12","author":"Joyner","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.transci.2022.103455_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2021.102548","article-title":"Effectiveness of convalescent plasma in indian patients with COVID-19","volume":"88","author":"Budhiraja","year":"2021","journal-title":"Blood Cells Mol Dis"},{"issue":"8","key":"10.1016\/j.transci.2022.103455_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.transci.2022.103455_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.transci.2022.103455_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102794","article-title":"Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID-19 patients: a rousing message of clinical benefit to both donors and recipients alike","volume":"59","author":"Seghatchian","year":"2020","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"10.1016\/j.transci.2022.103455_bib9","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1111\/bjh.16814","article-title":"Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients","volume":"190","author":"Lanza","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2022.103455_bib10","unstructured":"Second Interim, National Guidance to Blood Transfusion Services in India in light of Covid-19 Pandemic. Available at: https:\/\/www.mohfw.gov.in\/pdf\/2ndNBTCGuidanceinLightofCOVID19Pandemic.pdf."},{"key":"10.1016\/j.transci.2022.103455_bib11","unstructured":"Ministry of Health and Family Welfare, Government of India. Guidelines on Clinical Management Protocol: of COVID\u201319, Version 4. Available at: https:\/\/www.mohfw.gov.in\/pdf\/ClinicalManagementProtocolforCOVID19dated27062020.pdf."},{"key":"10.1016\/j.transci.2022.103455_bib12","unstructured":"Infectious Diseases Society of America. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Available at: https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/."},{"key":"10.1016\/j.transci.2022.103455_bib13","unstructured":"Indian Council of Medical Research, Evidence Based Advisory to address Inappropriate Use of Convalescent Plasma in COVID-19 Patients. Available at: https:\/\/www.icmr.gov.in\/pdf\/covid\/techdoc\/ICMR_ADVISORY_Convalescent_plasma_17112020_v1.pdf."},{"key":"10.1016\/j.transci.2022.103455_bib14","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/trf.15842","article-title":"COVID-19 convalescent plasma: phase 2","volume":"60","author":"Knudson","year":"2020","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.transci.2022.103455_bib15","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.mayocp.2021.02.008","article-title":"The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis","volume":"96","author":"Klassen","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.transci.2022.103455_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13613-021-00867-9","article-title":"Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study","volume":"11","author":"Hatzl","year":"2021","journal-title":"Ann Intensive Care."},{"issue":"2_suppl","key":"10.1016\/j.transci.2022.103455_bib17","doi-asserted-by":"crossref","first-page":"140S","DOI":"10.1177\/0145561320972608","article-title":"Risk factors for mortality in 220 patients with COVID-19 in Wuhan, China: a single-center, retrospective study","volume":"100","author":"Zhou","year":"2021","journal-title":"Ear Nose Throat J"},{"issue":"11","key":"10.1016\/j.transci.2022.103455_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241541","article-title":"Factors associated with disease severity and mortality among patients with COVID-19: a systematic review and meta-analysis","volume":"15","author":"Chidambaram","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.transci.2022.103455_bib19","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.3390\/jcm10092042","article-title":"Impact of Kidney Failure on the Severity of COVID-19","volume":"10","author":"Zar\u0119bska-Michaluk","year":"2021","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.transci.2022.103455_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254453","article-title":"Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19","volume":"16","author":"Briggs","year":"2021","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.transci.2022.103455_bib21","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00277-020-04169-1","article-title":"Blood type and outcomes in patients with COVID-19","volume":"99","author":"Latz","year":"2020","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.transci.2022.103455_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2478\/jtim-2021-0029","article-title":"Convalescent plasma for coronavirus disease 2019: dose is the key","volume":"9","author":"Yu","year":"2021","journal-title":"J Transl Int Med"},{"issue":"11","key":"10.1016\/j.transci.2022.103455_bib23","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2031893","article-title":"Convalescent plasma antibody levels and the risk of death from Covid-19","volume":"384","author":"Joyner","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2022.103455_bib24","doi-asserted-by":"crossref","unstructured":"K\u00f6rper S., Weiss M., Zickler D., et al., 2021. High dose convalescent plasma in COVID-19: results from the randomized trial CAPSID.medRxiv2021:2021.05.10.21256192.","DOI":"10.1101\/2021.05.10.21256192"},{"issue":"4","key":"10.1016\/j.transci.2022.103455_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinmicnews.2021.02.001","article-title":"Convalescent plasma for infectious diseases: historical framework and use in COVID-19","volume":"43","author":"Ripoll","year":"2021","journal-title":"Clin Microbiol Newsl"},{"key":"10.1016\/j.transci.2022.103455_bib26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1084\/jem.17.5.553","article-title":"The Results of the Serum Treatment in Thirteen Hundred Cases of Epidemic Meningitis","volume":"17","author":"Flexner","year":"1913","journal-title":"J Exp Med"},{"key":"10.1016\/j.transci.2022.103455_bib27","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","article-title":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients","author":"Soo","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.transci.2022.103455_bib28","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0140-6736(79)92335-3","article-title":"Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome","volume":"2","author":"Maiztegui","year":"1979","journal-title":"Lancet."},{"key":"10.1016\/j.transci.2022.103455_bib29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transci.2022.103455_bib30","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jinf.2016.11.009","article-title":"Evaluation of convalescent whole blood for treating Ebola Virus disease in Freetown, Sierra Leone","volume":"74","author":"Sahr","year":"2017","journal-title":"J Infect"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050222001288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050222001288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:56:21Z","timestamp":1761468981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050222001288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1473050222001288"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2022.103455","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patients","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2022.103455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103455"}}